Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis

Leukemia and Lymphoma

Volumn 56, Issue 9, 2015, Pages 2493-2497

  Mascarenhas, John ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

cytokines; inhibitor; JAK; Myelofibrosis; rationale

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CILIARY NEUROTROPHIC FACTOR; ETANERCEPT; FILGOTINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INCB 039110; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; JANUS KINASE 1; JANUS KINASE INHIBITOR; LEPTIN; MOMELOTINIB; PACRITINIB; PROLACTIN; RUXOLITINIB; STAT PROTEIN; UNCLASSIFIED DRUG; AUTACOID; CYTOKINE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER THERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; DISEASE ASSOCIATION; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULAR BIOLOGY; MYELOFIBROSIS; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; PRIMARY MYELOFIBROSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

CYTOKINES; HUMANS; INFLAMMATION MEDIATORS; JANUS KINASE 1; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84946038609     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1004670     Document Type: Review

References (37)

1. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
2. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.
3. Oh ST, Simonds EF, Jones C, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 2010; 116: 988-992.
4. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
5. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807.
6. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798.
7. Kremyanskaya M, Mascarenhas J, Rampal R, et al. Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. Br J Haematol 2014; 167: 144-6.
8. Gotlib J. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. Hematology Am Soc Hematol Educ Prog 2013: 529-537.
9. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60: 1895-1905.
10. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003; 3: 900-911.
11. Baker SJ, Rane SG, Reddy EP. Hematopoietic cytokine receptor signaling. Oncogene 2007; 26: 6724-6737.
12. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004; 5: 253.
13. Staerk J, Kallin A, Demoulin JB, et al. JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-Dalk with IGF1 receptor. J Biol Chem 2005; 280: 41893-41899.
14. Watowich SS, Wu H, Socolovsky M, et al. Cytokine receptor signal transduction and the control of hematopoietic cell development. Annu Rev Cell Dev Biol 1996; 12: 91-128.
15. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma© family cytokines. Nat Rev Immunol 2009; 9: 480-490.
16. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol 2007; 178: 2623-2629.
17. Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol 2011; 18: 314-323.
18. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998; 93: 373-383.
19. Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013; 191: 3568-3577.
20. Newcomb DC, Boswell MG, Zhou W, et al. Human TH17 cells express a functional IL-13 receptor and IL-13 attenuates IL-17A production. J Allergy Clin Immunol 2011; 127: 1006-1013 e1-e4.
21. Vanhouttte F, Mazur M, Van der Aa A, et al. Selective JAK1 inhibition in the treatment of rheumatoid arthritis: proof of concept with GLPG0634. Arthritis Rheum 2012; 64(Suppl. 10): Abstract 2489.
22. Namour F, Galien R, Gheyle R, et al. Once daily high dose regimens of GLPG0634 in healthy volunteers are safe and provide continuous inhibition of JAK1 but not JAK2. Arthritis Rheum. 2012; 64(Suppl. 10): Abstract 1331.
23. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363: 1117-1127.
24. Verstovsek S, Passamonti F, Rambaldi A, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 2014; 120: 513-520.
25. Verstovsek S, Mesa R, Salama ME, et al. Phase I study Of LY2784544, a JAK2 selective inhibitor, in patients with myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). Blood 2013; 122 (Suppl. 1): Abstract 665.
26. Komrokji RS, Wadleigh M, Seymour JF, et al. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Blood 2011; 118 (Suppl. 1): Abstract 282.
27. Ma L, Clayton JR, Walgren RA, et al. Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J 2013; 3: e109.
28. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109-3117.
29. Bissonnette R, Menter A, Fidelus-Gort R, et al. INCB018424 topical JAK1/JAK2 inhibitor: a double-blind, placebo-controlled study exploring the safety, tolerability, and efficacy of a 28-day course of escalating doses of an oral JAK 1 inhibitor (INCB039110) in subjects with stable, chronic plaque psoriasis. Presented at the European Academy of Dermatology and Venereology, Istanbul, Turkey, 3 October 2013.
30. Mascarenhas J, Talpaz M, Gupta V, et al. An open-label, phase II study of the JAK1 inhibitor INCB039110 in patients with myelofibrosis. Blood 2013; 122 (Suppl. 1): Abstract 663.
31. Mascarenhas JO, Orazi A, Bhalla KN, et al. Advances in myelofibrosis: a clinical case approach. Haematologica 2013; 98: 1499-1509.
32. Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012; 2012: 389-96.
33. Zenatti PP, Ribeiro D, Li W, et al. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 2011; 43: 932-939.
34. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356-1363.
35. Ghoreschi K, Laurence A, OShea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228: 273-287.
36. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia 2011; 25: 1751-1759.
37. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood 2010; 115: 5232-5240.